
	<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
	<html><head>
	<meta http-equiv="content-type" content="text/html; charset=windows-1252">
	<title>Xapian_query_results_NEAR</title>
	</head>
	<body>

	<table border="1" width="100%">
	  <tbody><tr>
		<th>Rank</th>
		<th>PubMed-ID</th>
		<th>Title (query term highlighted)</th>
	  </tr>
	<tr><td>0</td><td>22472062</td><td>Cardiovascular disease (<b>CVD</b>) limbo: how soon and low should we go to prevent <b>CVD</b> in <b>diabetes</b>?</td></tr><tr><td>1</td><td>28245267</td><td>Knowledge of risk factors for <b>diabetes</b> or cardiovascular disease (<b>CVD</b>) is poor among individuals with risk factors for <b>CVD</b>.</td></tr><tr><td>2</td><td>19931497</td><td><b>Diabetes</b> therapy and cancer; <b>diabetes</b> and <b>CVD</b> in people with severe mental illness--thoughts from Vienna.</td></tr><tr><td>3</td><td>20577298</td><td><b>Diabetes</b>: glycated hemoglobin is a marker of <b>diabetes</b> and <b>CVD</b> risk.</td></tr><tr><td>4</td><td>29365466</td><td>Apabetalone (RVX-208) may lower <b>CVD</b> events in <b>diabetes</b> mellitus by affecting complement pathway and microbiome activity.</td></tr><tr><td>5</td><td>27811933</td><td><b>Diabetes</b>: Lipidomics refines <b>CVD</b> risk prediction.</td></tr><tr><td>6</td><td>27750299</td><td>In patients with type 2 <b>diabetes</b> and <b>CVD</b>, empagliflozin reduced incident or worsening nephropathy at 3.1 y.</td></tr><tr><td>7</td><td>22641078</td><td>Chronic kidney disease: Albuminuria or CKD stage as best marker of <b>CVD</b> in <b>diabetes</b>?</td></tr><tr><td>8</td><td>25348438</td><td>Gestational <b>diabetes</b> is a significant <b>CVD</b> risk factor.</td></tr><tr><td>9</td><td>24935121</td><td>Therapy: Statin potency is associated with risk of new-onset <b>diabetes</b> in patients with <b>CVD</b>.</td></tr><tr><td>10</td><td>18958921</td><td>Intense <b>diabetes</b> treatment & <b>CVD</b>.</td></tr><tr><td>11</td><td>17425910</td><td>The role of PPAR-alpha agonists in the prevention of <b>CVD</b> in <b>diabetes</b>.</td></tr><tr><td>12</td><td>17181119</td><td>North Carolina initiative targets <b>CVD</b> and <b>diabetes</b> with telehealth intervention.</td></tr><tr><td>13</td><td>17213107</td><td>Long term fenofibrate did not reduce major coronary events but may reduce total <b>CVD</b> events in type 2 <b>diabetes</b>.</td></tr><tr><td>14</td><td>19192416</td><td>Inhibition of the RAS and prevention of <b>diabetes</b> and <b>CVD</b>: mechanistic insights and lessons learned from clinical trials.</td></tr><tr><td>15</td><td>16646609</td><td>Long-term fenofibrate therapy did not reduce major coronary events but may reduce total <b>CVD</b> events in type 2 <b>diabetes</b> mellitus.</td></tr><tr><td>16</td><td>16522276</td><td>Endothelial function and the prediction of <b>CVD</b> in <b>diabetes</b>.</td></tr><tr><td>17</td><td>14964157</td><td>Use it or lose it: exercise, <b>diabetes</b> and <b>CVD</b>.</td></tr><tr><td>18</td><td>20643979</td><td>Etiology. Higher "normal" glycated hemoglobin levels were associated with increased risk for <b>diabetes</b>, <b>CVD</b>, stroke, and mortality in adults.</td></tr><tr><td>19</td><td>20104677</td><td>Which risk engines are best to assess <b>CVD</b> risk in <b>diabetes</b>?</td></tr><tr><td>20</td><td>18060606</td><td>[Comprehensive care: <b>CVD</b> and <b>diabetes</b> mellitus].</td></tr><tr><td>21</td><td>17254512</td><td>Antioxidants and <b>CVD</b> in <b>diabetes</b>: where do we stand now.</td></tr><tr><td>22</td><td>16879779</td><td>The metabolic syndrome and endothelial dysfunction: common highway to type 2 <b>diabetes</b> and <b>CVD</b>.</td></tr><tr><td>23</td><td>24078317</td><td>Preventing type 2 <b>diabetes</b>, <b>CVD</b>, and mortality: surgical versus non-surgical weight loss strategies.</td></tr><tr><td>24</td><td>25894803</td><td>Next generation of weight management medications: implications for <b>diabetes</b> and <b>CVD</b> risk.</td></tr><tr><td>25</td><td>12880690</td><td>Pre-<b>diabetes</b>, insulin resistance, inflammation and <b>CVD</b> risk.</td></tr><tr><td>26</td><td>27741980</td><td><b>Diabetes</b> and Clinical and Subclinical <b>CVD</b>.</td></tr><tr><td>27</td><td>17349070</td><td>On the supposed influence of milk homogenization on the risk of <b>CVD</b>, <b>diabetes</b> and allergy.</td></tr><tr><td>28</td><td>16621114</td><td>Microalbuminuria presents the same vascular risk as overt <b>CVD</b> in type 2 <b>diabetes</b>.</td></tr><tr><td>29</td><td>17630950</td><td>Advanced glycation end products (AGEs) and cardiovascular disease (<b>CVD</b>) in <b>diabetes</b>.</td></tr><tr><td>30</td><td>18521688</td><td>Development and pilot evaluation of literacy-adapted <b>diabetes</b> and <b>CVD</b> education in urban, diabetic African Americans.</td></tr><tr><td>31</td><td>26411567</td><td>Approach to <b>diabetes</b> management in patients with <b>CVD</b>.</td></tr><tr><td>32</td><td>25736026</td><td>Insulin sensitivity and arterial stiffness in youth with type 1 <b>diabetes</b>: the SEARCH <b>CVD</b> study.</td></tr><tr><td>33</td><td>15682775</td><td>A qualitative assessment of Charlotte REACH: an ecological perspective for decreasing <b>CVD</b> and <b>diabetes</b> among African Americans.</td></tr><tr><td>34</td><td>20003638</td><td>Session 4: <b>CVD</b>, <b>diabetes</b> and cancer: Evidence for the use of the Mediterranean diet in patients with CHD.</td></tr><tr><td>35</td><td>19968905</td><td>Session 4: <b>CVD</b>, <b>diabetes</b> and cancer: Diet, insulin resistance and <b>diabetes</b>: the right (pro)portions.</td></tr><tr><td>36</td><td>18717208</td><td>A faith-based screeningeducation program for <b>diabetes</b>, <b>CVD</b>, and stroke in rural African Americans.</td></tr><tr><td>37</td><td>29017904</td><td>Spicing up your advice for South Asian and Anglo-Australians with type 2 <b>diabetes</b> and <b>CVD</b>: Do cultural constructions of diet matter?</td></tr><tr><td>38</td><td>22961570</td><td>Reduced heart rate variability among youth with type 1 <b>diabetes</b>: the SEARCH <b>CVD</b> study.</td></tr><tr><td>39</td><td>25211055</td><td><b>Diabetes</b> and <b>CVD</b> risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients.</td></tr><tr><td>40</td><td>17343775</td><td>Mechanisms of the components of the metabolic syndrome that predispose to <b>diabetes</b> and atherosclerotic <b>CVD</b>.</td></tr><tr><td>41</td><td>24267441</td><td>Progress in national and regional guidelines development and deployment for the clinical prevention and control of <b>CVD</b> and <b>diabetes</b> in Africa.</td></tr><tr><td>42</td><td>26721813</td><td>Predictors of Increased Carotid Intima-Media Thickness in Youth With Type 1 <b>Diabetes</b>: The SEARCH <b>CVD</b> Study.</td></tr><tr><td>43</td><td>24450411</td><td>Cardiovascular health in adolescents with type 1 <b>diabetes</b>: the SEARCH <b>CVD</b> study.</td></tr><tr><td>44</td><td>25741874</td><td>Medicare Star excludes <b>diabetes</b> patients with poor <b>CVD</b> risk factor control.</td></tr><tr><td>45</td><td>25912292</td><td>Arterial stiffness in adolescents and young adults with and without type 1 <b>diabetes</b>: the SEARCH <b>CVD</b> study.</td></tr><tr><td>46</td><td>12698956</td><td>Evidence for joint action of genes on <b>diabetes</b> status and <b>CVD</b> risk factors in American Indians: the strong heart family study.</td></tr><tr><td>47</td><td>24010960</td><td>Impact of glycemic control on heart rate variability in youth with type 1 <b>diabetes</b>: the SEARCH <b>CVD</b> study.</td></tr><tr><td>48</td><td>19968904</td><td>Session 4: <b>CVD</b>, <b>diabetes</b> and cancer: A dietary portfolio for management and prevention of heart disease.</td></tr><tr><td>49</td><td>24101697</td><td>Cardiovascular risk factors are associated with increased arterial stiffness in youth with type 1 <b>diabetes</b>: the SEARCH <b>CVD</b> study.</td></tr><tr><td>50</td><td>24636522</td><td>High serum phosphate and triglyceride levels in smoking women and men with <b>CVD</b> risk and type 2 <b>diabetes</b>.</td></tr><tr><td>51</td><td>23670978</td><td>Variants in adiponectin signaling pathway genes show little association with subclinical <b>CVD</b> in the <b>diabetes</b> heart study.</td></tr><tr><td>52</td><td>17391554</td><td>Whole grain intake and its cross-sectional association with obesity, insulin resistance, inflammation, <b>diabetes</b> and subclinical <b>CVD</b>: The MESA Study.</td></tr><tr><td>53</td><td>23435158</td><td>Reduced heart rate variability is associated with increased arterial stiffness in youth with type 1 <b>diabetes</b>: the SEARCH <b>CVD</b> study.</td></tr><tr><td>54</td><td>24168904</td><td>Associations between dairy protein intake and body weight and risk markers of <b>diabetes</b> and <b>CVD</b> during weight maintenance.</td></tr><tr><td>55</td><td>17535429</td><td>Differences in the quality of primary medical care for <b>CVD</b> and <b>diabetes</b> across the NHS: evidence from the quality and outcomes framework.</td></tr><tr><td>56</td><td>28575229</td><td>The Relationship Between the Score on a Simple Measure of Cognitive Function and Incident <b>CVD</b> in People With <b>Diabetes</b>: A Post Hoc Epidemiological Analysis From the ACCORD-MIND Study.</td></tr><tr><td>57</td><td>24073676</td><td>Effectiveness of the fixed-dose combination of olmesartanamlodipinehydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and <b>diabetes</b>, CKD and chronic <b>CVD</b>.</td></tr><tr><td>58</td><td>28771923</td><td>Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 <b>diabetes</b> (<b>CVD</b>-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.</td></tr>
	</tbody></table>

	</body></html>
	